NCT00089479View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

2,611

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

June 30, 2010

Study Completion Date

May 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

capecitabine [Xeloda]

825mg/m2 po bid on days 1-14 of each 3 week cycle

DRUG

Taxotere

75mg/m2 iv on day 1 of each 3 week cycle

DRUG

Taxotere

100mg/m2 iv on day 1 of each 3 week cycle

Trial Locations (1)

77060

Houston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00089479 - A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer | Biotech Hunter | Biotech Hunter